ArticleScientific reports2025
Prevalence and health checkup-based detection of metabolic dysfunction-associated steatotic liver disease in Japanese young adults.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We aimed to elucidate the prevalence of steatotic liver disease (SLD) in Japanese young adults and to identify health checkup-based markers for metabolic dysfunction-associated steatotic liver disease (MASLD). We recruited participants (18–29 years) attending a health checkup. Abdominal ultrasonography and health checkup data were used to diagnose and classify SLD. The diagnostic ability of serum alanine aminotransferase (ALT), fatty liver index (FLI), and hepatic steatosis index (HSI) were evaluated using receiver operating characteristic curve analysis. Among the 1632 participants in 2023, 1004 (62%) were male, and SLD was observed in 271 (17%). In the SLD subclass, 143 (9%), 1 (< 1%), 0 (0%), and 127 (8%) were diagnosed with MASLD, MASLD with moderate alcohol intake, alcohol-associated/related liver disease, and cryptogenic SLD, respectively. The area under the curve of ALT, FLI, and HSI to identify MASLD were 0.76, 0.85, and 0.84, respectively. The cutoff value of ALT to rule in (specificity 0.90) MASLD was 31 IU/L. Similar results were observed in 1743 participants in 2024. In conclusion, the prevalence of SLD and MASLD in Japanese young adults was 17% and 9%, respectively. ALT > 30 IU/L was identified as a reasonable cutoff value to identify MASLD in Japanese young adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.